Cargando…
Differential effects of neurodegeneration biomarkers on subclinical cognitive decline
INTRODUCTION: Neurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer's disease. We test whether t-tau and alternative biomarkers of neurodegeneration—neurogranin and neurofilament light protein (NFL)—add value in predicting subclinical cognitiv...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462765/ https://www.ncbi.nlm.nih.gov/pubmed/31011623 http://dx.doi.org/10.1016/j.trci.2019.02.004 |
_version_ | 1783410635255578624 |
---|---|
author | Merluzzi, Andrew P. Vogt, Nicholas M. Norton, Derek Jonaitis, Erin Clark, Lindsay R. Carlsson, Cynthia M. Johnson, Sterling C. Asthana, Sanjay Blennow, Kaj Zetterberg, Henrik Bendlin, Barbara B. |
author_facet | Merluzzi, Andrew P. Vogt, Nicholas M. Norton, Derek Jonaitis, Erin Clark, Lindsay R. Carlsson, Cynthia M. Johnson, Sterling C. Asthana, Sanjay Blennow, Kaj Zetterberg, Henrik Bendlin, Barbara B. |
author_sort | Merluzzi, Andrew P. |
collection | PubMed |
description | INTRODUCTION: Neurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer's disease. We test whether t-tau and alternative biomarkers of neurodegeneration—neurogranin and neurofilament light protein (NFL)—add value in predicting subclinical cognitive decline. METHODS: One hundred fifty cognitively unimpaired participants received a lumbar puncture for cerebrospinal fluid and at least two neuropsychological examinations (mean age at first visit = 59.3 ± 6.3 years; 67% female). Linear mixed effects models were used with cognitive composite scores as outcomes. Neurodegeneration interactions terms were the primary predictors of interest: age × NFL or age × neurogranin or age × t-tau. Models were compared using likelihood ratio tests. RESULTS: Age × NFL accounted for a significant amount of variation in longitudinal change on preclinical Alzheimer's cognitive composite scores, memory composite scores, and learning scores, whereas age × neurogranin and age × t-tau did not. DISCUSSION: These data suggest that NFL may be more sensitive to subclinical cognitive decline compared to other proposed biomarkers for neurodegeneration. |
format | Online Article Text |
id | pubmed-6462765 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-64627652019-04-22 Differential effects of neurodegeneration biomarkers on subclinical cognitive decline Merluzzi, Andrew P. Vogt, Nicholas M. Norton, Derek Jonaitis, Erin Clark, Lindsay R. Carlsson, Cynthia M. Johnson, Sterling C. Asthana, Sanjay Blennow, Kaj Zetterberg, Henrik Bendlin, Barbara B. Alzheimers Dement (N Y) Featured Article INTRODUCTION: Neurodegeneration appears to be the biological mechanism most proximate to cognitive decline in Alzheimer's disease. We test whether t-tau and alternative biomarkers of neurodegeneration—neurogranin and neurofilament light protein (NFL)—add value in predicting subclinical cognitive decline. METHODS: One hundred fifty cognitively unimpaired participants received a lumbar puncture for cerebrospinal fluid and at least two neuropsychological examinations (mean age at first visit = 59.3 ± 6.3 years; 67% female). Linear mixed effects models were used with cognitive composite scores as outcomes. Neurodegeneration interactions terms were the primary predictors of interest: age × NFL or age × neurogranin or age × t-tau. Models were compared using likelihood ratio tests. RESULTS: Age × NFL accounted for a significant amount of variation in longitudinal change on preclinical Alzheimer's cognitive composite scores, memory composite scores, and learning scores, whereas age × neurogranin and age × t-tau did not. DISCUSSION: These data suggest that NFL may be more sensitive to subclinical cognitive decline compared to other proposed biomarkers for neurodegeneration. Elsevier 2019-04-12 /pmc/articles/PMC6462765/ /pubmed/31011623 http://dx.doi.org/10.1016/j.trci.2019.02.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Featured Article Merluzzi, Andrew P. Vogt, Nicholas M. Norton, Derek Jonaitis, Erin Clark, Lindsay R. Carlsson, Cynthia M. Johnson, Sterling C. Asthana, Sanjay Blennow, Kaj Zetterberg, Henrik Bendlin, Barbara B. Differential effects of neurodegeneration biomarkers on subclinical cognitive decline |
title | Differential effects of neurodegeneration biomarkers on subclinical cognitive decline |
title_full | Differential effects of neurodegeneration biomarkers on subclinical cognitive decline |
title_fullStr | Differential effects of neurodegeneration biomarkers on subclinical cognitive decline |
title_full_unstemmed | Differential effects of neurodegeneration biomarkers on subclinical cognitive decline |
title_short | Differential effects of neurodegeneration biomarkers on subclinical cognitive decline |
title_sort | differential effects of neurodegeneration biomarkers on subclinical cognitive decline |
topic | Featured Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462765/ https://www.ncbi.nlm.nih.gov/pubmed/31011623 http://dx.doi.org/10.1016/j.trci.2019.02.004 |
work_keys_str_mv | AT merluzziandrewp differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT vogtnicholasm differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT nortonderek differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT jonaitiserin differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT clarklindsayr differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT carlssoncynthiam differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT johnsonsterlingc differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT asthanasanjay differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT blennowkaj differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT zetterberghenrik differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline AT bendlinbarbarab differentialeffectsofneurodegenerationbiomarkersonsubclinicalcognitivedecline |